Skip to content

Stryker SYK Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
CONMED logo
CONMEDCNMD
$10.58M-72.0%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-$28.27M-12.5%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Vericel logo
VericelVCEL
$15.13M+299%

Other financials

Income statement

See full
Revenue$6.0B+2.6%
Gross profit$3.8B+1.8%
Operating income$936.0M+11.8%
Net income$745.0M+13.9%
EPS (diluted)$1.93+14.2%

Balance sheet

See full
Cash & equivalents$2.9B+24.1%
Total debt$14.4B-15.1%
Total assets$46.3B+0.6%

Cash flow

See full
Operating cash flow$581.0M+132%
CapEx$166.0M+35.0%

Valuation

See full
Market cap$121.18B-15.6%
Enterprise value$132.69B-16.1%
P/E36.3×-13.9×
P/S4.8×-1.4×

Profitability

See full
Gross margin63.8%-0.1pp
Operating margin19.7%+4.4pp
Net margin13.2%+0.9pp
FCF margin18.1%+2.7pp

Returns & leverage

See full
Return on equity32.8%
Debt / equity0.8×
Current ratio2.1×+0.5×

Where this comes from

Calculated from Stryker’s reported figures.

The official record: Stryker’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stryker's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stryker's free cash flow?
Stryker (SYK) reported free cash flow of $415M in Q1 2026.
How has Stryker's free cash flow changed year-over-year?
Stryker's free cash flow increased by 226.8% year-over-year, from $127M to $415M.
What is the long-term trend for Stryker's free cash flow?
Over 4 years (2021 to 2025), Stryker's free cash flow has grown at a 11.8% compound annual growth rate (CAGR), from $2.74B to $4.28B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.